Aeolus Pharmaceuticals, Inc.:製品開発パイプライン動向2015

◆英語タイトル:Aeolus Pharmaceuticals, Inc. - Product Pipeline Review - 2015
◆商品コード:GMDHC06841CDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年3月11日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Aeolus Pharmaceuticals, Inc. – Product Pipeline Review – 2015

Summary

Global Markets Direct’s, ‘Aeolus Pharmaceuticals, Inc. – Product Pipeline Review – 2015’, provides an overview of the Aeolus Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aeolus Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Aeolus Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Aeolus Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Aeolus Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate Aeolus Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Aeolus Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Aeolus Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Aeolus Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aeolus Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Aeolus Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Aeolus Pharmaceuticals, Inc. Snapshot 5
Aeolus Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Aeolus Pharmaceuticals, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Aeolus Pharmaceuticals, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Aeolus Pharmaceuticals, Inc. – Pipeline Products Glance 10
Aeolus Pharmaceuticals, Inc. – Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Aeolus Pharmaceuticals, Inc. – Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Aeolus Pharmaceuticals, Inc. – Drug Profiles 13
AEOL-10150 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
AEOL-1114B 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AEOL-11203 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
AEOL-11207 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AEOL-10171 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Aeolus Pharmaceuticals, Inc. – Pipeline Analysis 20
Aeolus Pharmaceuticals, Inc. – Pipeline Products by Target 20
Aeolus Pharmaceuticals, Inc. – Pipeline Products by Route of Administration 21
Aeolus Pharmaceuticals, Inc. – Pipeline Products by Molecule Type 22
Aeolus Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action 23
Aeolus Pharmaceuticals, Inc. – Recent Pipeline Updates 24
Aeolus Pharmaceuticals, Inc. – Dormant Projects 30
Aeolus Pharmaceuticals, Inc. – Discontinued Pipeline Products 31
Discontinued Pipeline Product Profiles 31
deligoparin sodium 31
AEOL-10150 31
Aeolus Pharmaceuticals, Inc. – Company Statement 32
Aeolus Pharmaceuticals, Inc. – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

[List of Tables]
Aeolus Pharmaceuticals, Inc., Key Information 5
Aeolus Pharmaceuticals, Inc., Key Facts 5
Aeolus Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Aeolus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Aeolus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Aeolus Pharmaceuticals, Inc. - Phase I, 2015 10
Aeolus Pharmaceuticals, Inc. - Preclinical, 2015 11
Aeolus Pharmaceuticals, Inc. - Discovery, 2015 12
Aeolus Pharmaceuticals, Inc. - Pipeline by Target, 2015 20
Aeolus Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 21
Aeolus Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 22
Aeolus Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 23
Aeolus Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 24
Aeolus Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 30
Aeolus Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 31
Aeolus Pharmaceuticals, Inc., Subsidiaries 34

[List of Figures]
Aeolus Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015 7
Aeolus Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Aeolus Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Aeolus Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015 20
Aeolus Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015 21
Aeolus Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015 22
Aeolus Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 23

【レポートのキーワード】

Aeolus Pharmaceuticals, Inc.、製品開発、製薬、医薬品、治験、研究開発、パイプライン

★調査レポート[Aeolus Pharmaceuticals, Inc.:製品開発パイプライン動向2015] (コード:GMDHC06841CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[Aeolus Pharmaceuticals, Inc.:製品開発パイプライン動向2015]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆